MDCX - Latest News

Medicus Pharma Ltd. Common Stock (MDCX), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $4.1M. Beta to the broader market is -0.61.

The article list below shows the most recent MDCX headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent MDCX Headlines

Medicus Pharma targets partnerships and clinical milestones as oncology pipeline advances

proactiveinvestors.com - Oct 8, 2026

Medicus Pharma (NASDAQ:MDCX) is positioning its precision oncology-led pipeline for a series of clinical and regulatory milestones, with partnerships

Medicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term Value

globenewswire.com - Oct 8, 2026

PHILADELPHIA, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd.

Medicus Pharma files streamlined Phase 2b/3 prostate cancer trial design with FDA

proactiveinvestors.com - Sep 29, 2026

Medicus Pharma (NASDAQ:MDCX) has submitted a seamless Phase 2b/3 registration-intent protocol to the US Food and Drug Administration for Teverelix, it

Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer

globenewswire.com - Sep 29, 2026

Proposed seamless design would incorporate previously FDA-cleared dose-optimization work into a single registration-intent program aligning it with Co

Medicus Pharma to focus SkinJect development exclusively on Gorlin syndrome patients

proactiveinvestors.com - Sep 21, 2026

Medicus Pharma (NASDAQ:MDCX) said it will focus future internally sponsored clinical development of SkinJect exclusively on Gorlin syndrome patients w

How News Affects MDCX Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track MDCX's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked MDCX news questions

What is the latest MDCX news headline?

The most recent MDCX headline (Oct 8, 2026) is "Medicus Pharma targets partnerships and clinical milestones as oncology pipeline advances". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the MDCX news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What MDCX news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual MDCX options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.